. UCLA Staging Ti: Tumor involving the nasal cavity and/or paranasal sinuses (excluding sphenoid), sparing the most superior ethmoidal cells T2: Tumor involving the nasal cavity and/or paranasal sinuses (including the sphenoid) with extension to or erosion of the cribriform plate T3: Tumor extending into the orbit or protruding into the anterior cranial fossa T4: Tumor involving the brain Thirty-two patients were identified for this review, 20 patients with ON and 12 with NEC. Figure 1 shows the findings characteristic of ON: irregular groups of tumor cells separated by acellular fibrillar material, tumor cells that form Homer-Wright rosettes or olfactory rosettes, and tumor cells with scant cytoplasm and uniform nuclear chromatin with or without nucleoli (Fig. 2) . NEC exhibits poorly differentiated nests of cells separated by thin branches of cellular connective tissue, tumor cells with scant to moderate cytoplasm, finely granular nuclear chromatin, the absence of prominent nucleoli and fibrillar "cob web"-like material, and the presence of tumor intimately associated with benign glandular epithelium (Figs. 3, 4) . NEC is a distinct category with poor histologic differentiations and neuroendocrine features.
For living patients, the median follow-up was 3 years (range, 18 months to 23 years). The median age at diagnosis was 40 years for patients with ON (range, 10 months to 79 years) and 53 years for patients with NEC (range, 16 to 79 years). The male to female ratio for ON was 1.9:1 and for NEC, 1.4:1. The origin of the disease, based on clinical findings, was the ethmoid sinuses (55% for ON, 42% for NEC) or nasal cavity (30% for ON, 50% for NEC). The predominant presenting symptom for both ON and NEC was nasal obstruction (65% and 75%, respectively), and the second most common symptom was epistaxis. Examination characteristically revealed a nasal mass in more than 80% of patients in both groups. Cranial nerve involvement (excluding CN I) was surprisingly rare, occurring in less than 10% of patients in both groups. There was no statistical association between the use of tobacco or other known carcinogens and the development of these tumors. The UCLA stages of disease for all patients are presented in Table 2 . Regional metastasis at AW ow.w*,.;tO0ev>'s t5H,*>_m^Figure 1. Nasal neuroblastoma. the time of diagnosis was uncommon in both groups: two patients with ON and one patient with NEC had neck metastasis.
A treatment summary is presented in Twenty-seven of the 32 patients received radio- Eleven patients (55%) with ON did not develop recurrence during the time of follow-up, whereas nine (45%) did develop recurrence. The median time to recurrence was 6 months for a primary recurrence (n = 4) and 30 months for the development of regional disease (n = 4). Only one patient in this group developed distant metastasis; this patient was a 10-month-old female for whom the metastasis proved to be fatal. In the four (18%) patients who developed regional disease, all responded to salvage therapy that included chemotherapy, radiation therapy, and surgery ( SKULL BASE SURGERY/VOLUME 6, NUMBER 1 JANUARY 1996 Because of the small number of patients in each group in this study, a Kaplan-Meier survival analysis could not be performed. Instead, a crude mortality analysis shows that for the 20 patients with ON, 10 (50%) were alive, at the time this report was prepared. Three patients (15%) were dead of other causes and were without disease. Two patients (10%) were living with disease (one was lost to follow-up), one (5%) died from other causes with disease, and three (15%) died Although their findings, like ours, did not reach statistical significance, their staging system had a higher association between stage and disease-free survival duration than either of the two earlier staging systems. Our series confirms the usefulness of this improved staging system. In our study only one ON patient with TI disease died, while more patients with more advanced tumors died from their disease or with disease present.
In two more recent publications, Zappia et a18 at the University of Michigan used the Kadish staging system, and Morita et a19 at the Mayo Clinic used a modification of the Kadish staging system. Because of the small number of patients treated at each institution, neither of these studies found a significant correlation between advanced stage and disease-free survival duration, although there was an association between recurrence and death from disease in both these studies in patients with advanced Kadish stage C disease. The Mayo Clinic material presented the largest number of patients (49) 
REVIEWERS' COMMENTS
We appreciate having the opportunity to comment on this study by Dr. Austin and his colleagues. They present a series of patients with either olfactory neuroblastoma or neuroendocrine carcinoma of the anterior skull base. This is a large series, carefully analyzed, from a major referral center. The pathologic differences in these lesions were described by Silva et al, at M.D. Anderson Cancer Center in 1982. 1 Nevertheless, problems arise because of the rarity of the tumor. These 32 patients presented over 38 years. There were significant differences in the technology available for imaging, as well as differences in the chemotherapy and surgery. Even a major referral center does not see many patients.
Although we make the pathologic distinctions between olfactory neuroblastoma and neuroendocrine carcinoma, we treat the tumors by the same protocol. The patient is first treated with two cycles of chemotherapy (etoposide and cis-platinum). If the tumor disappears or regresses dramatically by imaging, the patient is then radiated according to a high-dose proton/photon protocol. The patient then receives two additional cycles of chemotherapy. If the tumor does not regress significantly, and if the tumor is resectable by craniofacial resection, then surgical resection is recommended before radiation therapy.3 We have not noticed differences in the biologic behavior or clinical outcome between these two pathologic types. Ordonez and Mackay,2 who also reviewed the M.D. Anderson Cancer Center experience with these tumors, detailed the pathologic distinctions, but emphasized that there is a continuum with significant overlap. Our clinical approach emphasizes the overlap.
Since these tumors are well defined pathologically, especially with immune peroxidase stains and electron microscopy, and since imaging allows careful determination of the extent of the tumor before treatment, a multicenter pooling of data might be realistic. The North American Skull Base Society is an organization which could organize this study.
